Trogenix has raised $95 million in a Series A financing round to push forward its innovative "Trojan horse" modality aimed at treating brain cancer, starting with glioblastoma. The capital infusion will accelerate clinical development of its lead program as the company approaches the clinic. This ambitious approach targets the delivery of therapeutics across the blood-brain barrier, addressing a critical unmet need in neuro-oncology.